- Home
- COE vs IOBT Comparison
COE vs IOBT Comparison
Compare COE & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- IOBT
- Stock Information
- Founded
- COE 2011
- IOBT 2014
- Country
- COE Singapore
- IOBT Denmark
- Employees
- COE N/A
- IOBT N/A
- Industry
- COE Other Consumer Services
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- IOBT Health Care
- Exchange
- COE Nasdaq
- IOBT Nasdaq
- Market Cap
- COE 91.5M
- IOBT 81.7M
- IPO Year
- COE 2016
- IOBT 2021
- Fundamental
- Price
- COE $14.20
- IOBT $0.82
- Analyst Decision
- COE
- IOBT Strong Buy
- Analyst Count
- COE 0
- IOBT 3
- Target Price
- COE N/A
- IOBT $9.33
- AVG Volume (30 Days)
- COE 5.1K
- IOBT 303.0K
- Earning Date
- COE 12-16-2024
- IOBT 11-12-2024
- Dividend Yield
- COE N/A
- IOBT N/A
- EPS Growth
- COE N/A
- IOBT N/A
- EPS
- COE N/A
- IOBT N/A
- Revenue
- COE $35,705,000.00
- IOBT N/A
- Revenue This Year
- COE N/A
- IOBT N/A
- Revenue Next Year
- COE N/A
- IOBT N/A
- P/E Ratio
- COE N/A
- IOBT N/A
- Revenue Growth
- COE 66.41
- IOBT N/A
- 52 Week Low
- COE $6.00
- IOBT $0.73
- 52 Week High
- COE $19.75
- IOBT $2.10
- Technical
- Relative Strength Index (RSI)
- COE 41.35
- IOBT 30.51
- Support Level
- COE $14.01
- IOBT $0.86
- Resistance Level
- COE $15.00
- IOBT $1.29
- Average True Range (ATR)
- COE 0.56
- IOBT 0.12
- MACD
- COE -0.13
- IOBT -0.04
- Stochastic Oscillator
- COE 8.88
- IOBT 5.25
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.